Overview
Levilactobacillus brevis (formerly Lactobacillus brevis) is a Gram-positive, heterofermentative lactic acid bacterium found in the human gut and oral cavity, as well as in a variety of fermented foods including sauerkraut, kimchi, and artisanal cheeses. Reclassified to the genus Levilactobacillus in 2020, this species has gained significant attention as one of the most prolific producers of gamma-aminobutyric acid (GABA) among lactic acid bacteria, positioning it as a leading candidate for psychobiotic applications.
Beyond its GABA-producing capacity, L. brevis strains have been studied for oral health benefits, anti-allergic properties, and intestinal barrier strengthening. The species represents an interesting intersection of traditional fermented food microbiology and modern psychobiotic research.
Classification
L. brevis belongs to the family Lactobacillaceae within the phylum Bacillota (formerly Firmicutes). It is an obligately heterofermentative species, producing lactic acid, ethanol, and carbon dioxide from glucose. The type strain is ATCC 14869. The species is commonly isolated from plant-based fermented foods, dairy products, and the human gastrointestinal and oral microbiomes. Its heterofermentative metabolism distinguishes it from homofermentative lactobacilli and contributes to the complex flavor profiles of fermented foods.
Key Characteristics
The most notable characteristic of L. brevis is its capacity for high-level GABA biosynthesis. Certain strains, such as NCL912, have been reported to produce GABA at concentrations exceeding 103 mg/ml, among the highest reported for any lactic acid bacterium. GABA is the primary inhibitory neurotransmitter in the central nervous system, and emerging research suggests that microbially produced GABA in the gut may influence brain function through the gut-brain axis.
Studies indicate that GABA-producing L. brevis strains may also strengthen intestinal barrier function through upregulation of tight-junction proteins, potentially offering dual benefits for both neurological and digestive health. The species also demonstrates immunomodulatory properties, with GABA-containing fractions showing ATG5-dependent autophagy-mediated induction of anti-inflammatory cytokines IL-10 and TGF-beta.
Health Significance
The health significance of L. brevis spans neurological, oral, and immune domains. Research suggests that GABA-producing strains may be associated with improved cognitive reactivity to negative mood in human cohort studies, representing some of the first clinical evidence linking specific bacterial GABA production to mental health outcomes. These findings, while preliminary, position L. brevis as a promising psychobiotic candidate.
For oral health, strain CD2 has been studied for its ability to inhibit Streptococcus mutans, a primary causative agent of dental caries. In the allergy space, strain KB290 has demonstrated significant reductions in allergic symptoms in clinical trials involving cedar pollinosis patients, with effects correlated to suppressed Th2 cytokine responses. While additional large-scale human trials are needed across all these application areas, L. brevis represents a versatile probiotic species with a uniquely strong GABA-production profile.